{"generic":"Pixantrone Dimaleate","drugs":["Pixantrone Dimaleate"],"mono":{"0":{"id":"930367-s-0","title":"Generic Names","mono":"Pixantrone Dimaleate"},"1":{"id":"930367-s-1","title":"Dosing and Indications","sub":[{"id":"930367-s-1-4","title":"Adult Dosing","mono":"<ul><li>number of mg to administer based on body surface area (BSA); use body weight on day 1 of each cycle for institutional standard BSA calculation; evidence of BSA dosing in obese patients is limited<\/li><li>each pixantrone dimaleate vial contains pixantrone base 29 mg; use pixantrone base to calculate the required dose<\/li><li><b>Non-Hodgkin's lymphoma, Relapsed or refractory, aggressive, B-cell:<\/b> 50 mg\/m(2) pixantrone base by slow IV infusion over at least 60 minutes on days 1, 8, and 15 of each 28-day cycle for up to 6 cycles (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"930367-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients younger than 18 years "},{"id":"930367-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hematologic:<\/b> day 1 any cycle, delay therapy if absolute neutrophil count less than 1 X 10(9)\/L or if platelet count less than 75 X 10(9)\/L; may resume once levels meet or exceed 1 X 10(9)\/L and 75 X 10(9)\/L, respectively<\/li><li><b>hematologic:<\/b> day 8 or 15 any cycle, grade 1 to 2: platelets 50 X 10(9)\/L to lower limit normal (LLN) and absolute neutrophil count (ANC) 1 X 10(9)\/L to LLN, no dose or schedule adjustment; grade 3: platelet 25 to less than 50 X 10(9)\/L and ANC 0.5 to less than 1 X 10(9)\/L, delay therapy until platelet count 50 X 10(9)\/L or greater and ANC 1 X 10(9)\/L or greater; grade 4: platelets less than 25 X 10(9)\/L and ANC less than 0.5 X 10(9)\/L, delay therapy until platelet count 50 X 10(9)\/L or greater and ANC 1 X 10(9)\/L or greater and reduce dose by 20%<\/li><li><b>nonhematologic:<\/b> grade 3 or 4 drug-related NON-cardiac toxicity other than nausea and vomiting, delay therapy until recovery to grade 1 and reduce dose by 20%<\/li><li><b>nonhematologic:<\/b> grade 3 or 4 NYHA cardiovascular toxicity or persistent left ventricular ejection fraction decline, delay therapy and monitor until recovery; consider discontinuation for persistent LVEF decline of 15% or greater from baseline<\/li><li><b>hepatic impairment:<\/b> severe excretory, use not recommended<\/li><li><b>geriatric:<\/b> 65 years or older, no dose adjustment required<\/li><li><b>obesity:<\/b> use actual body weight for dose calculation in overweight, obese, or morbidly obese with BMI greater than 25; any standard formula for body surface area calculation acceptable (eg, Mosteller, Dubois and Dubois, Haycock, Gehan and George, or Boyd)<\/li><\/ul>"},{"id":"930367-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Non-Hodgkin's lymphoma, Relapsed or refractory, aggressive, B-cell<br\/>"}]},"3":{"id":"930367-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930367-s-3-9","title":"Contraindications","mono":"<ul><li>profound bone marrow suppression<\/li><li>severe hepatic dysfunction<\/li><li>hypersensitivity to pixantrone dimaleate or any components of the product<\/li><li>immunization with live virus vaccines<\/li><\/ul>"},{"id":"930367-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- cardiotoxicity, including decreased left ventricular ejection fraction or fatal congestive heart failure, may occur during or after treatment; monitoring recommended and temporary or permanent discontinuation may be necessary<\/li><li>-- active or dormant cardiovascular disease or risk factors (eg, baseline left ventricular ejection fraction less than 45%, NYHA grade 3 or 4, myocardial infarction within 6 months, doxorubicin or equivalent prior cumulative doses exceeding 450 mg\/m(2), severe arrhythmia, uncontrolled hypertension or angina) increases risk of cardiac toxicity; evaluate risk to benefit prior to therapy initiation and monitoring recommended<\/li><li>-- prior or concurrent radiotherapy to the mediastinal area increases risk of cardiac toxicity; monitoring recommended<\/li><li>Hepatic:<\/li><li>hepatic impairment, mild or moderate<\/li><li>Hematologic:<\/li><li>-- secondary hematological malignancies (eg, acute myeloid leukemia, myelodysplastic syndrome) during or after therapy have been reported<\/li><li>-- severe myelosuppression, including neutropenia (predominantly), leukopenia, anemia, thrombocytopenia, and lymphopenia, may occur; monitoring recommended and dose adjustment may be necessary<\/li><li>Immunologic:<\/li><li>-- severe infections (eg, pneumonia, cellulitis, bronchitis, sepsis) including hospitalization, septic shock, and death, have been reported; use not recommended in patients with active, severe, or history of recurrent or chronic infections, or underlying conditions predisposing to serious infections<\/li><li>Renal:<\/li><li>-- renal impairment<\/li><li>Reproductive:<\/li><li>-- use not recommended during pregnancy or in women not using contraception; men and women must use effective contraception during and up to 6 months after treatment<\/li><li>Other:<\/li><li>-- extravasation may occur; discontinue immediately and restart using another vein<\/li><li>-- photosensitivity may occur; protective clothing and sunscreen recommended<\/li><li>-- sodium-restricted diet; product contains approximately 1000 mg (43 mmol) sodium per dose after dilution<\/li><li>-- tumor lysis syndrome may occur; monitoring recommended in patients at high risk (elevated LDH, high tumor volume, high baseline uric acid or serum phosphate)<\/li><li>Concomitant use:<\/li><li>-- immunizations may be ineffective if given during therapy<\/li><li>-- previous anthracycline or anthracenedione exposure increases risk of cardiac toxicity; monitoring recommended<\/li><li>-- use with other cardiotoxic agents increases risk of cardiac toxicity; monitoring recommended<\/li><\/ul>"},{"id":"930367-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"930367-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"4":{"id":"930367-s-4","title":"Drug Interactions","sub":{"1":{"id":"930367-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Acetaminophen (theoretical)<\/li><li>Agomelatine (theoretical)<\/li><li>Alclometasone (theoretical)<\/li><li>Amcinonide (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amodiaquine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Beclomethasone (theoretical)<\/li><li>Betamethasone (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Budesonide (theoretical)<\/li><li>Caffeine (theoretical)<\/li><li>Captopril (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Carvedilol (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Ciclesonide (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clobetasol (theoretical)<\/li><li>Clobetasone (theoretical)<\/li><li>Clocortolone (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Cortisone (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Deflazacort (theoretical)<\/li><li>Desonide (theoretical)<\/li><li>Desoximetasone (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Diflorasone (theoretical)<\/li><li>Diflucortolone (theoretical)<\/li><li>Difluprednate (theoretical)<\/li><li>Diltiazem (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Duloxetine (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Eltrombopag (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Estradiol (theoretical)<\/li><li>Felodipine (theoretical)<\/li><li>Flucloronide (theoretical)<\/li><li>Flumethasone (theoretical)<\/li><li>Flunisolide (theoretical)<\/li><li>Fluocinolone (theoretical)<\/li><li>Fluocinonide (theoretical)<\/li><li>Fluocortin (theoretical)<\/li><li>Fluocortolone (theoretical)<\/li><li>Fluorometholone (theoretical)<\/li><li>Fluticasone (theoretical)<\/li><li>Fluvastatin (theoretical)<\/li><li>Fluvoxamine (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Halcinonide (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Hydrocortisone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Loteprednol (theoretical)<\/li><li>Methylprednisolone (theoretical)<\/li><li>Mexiletine (theoretical)<\/li><li>Mometasone (theoretical)<\/li><li>Montelukast (theoretical)<\/li><li>Nabumetone (theoretical)<\/li><li>Naproxen (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Phenacetin (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Prednicarbate (theoretical)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Propranolol (theoretical)<\/li><li>Quercetin (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rasagiline (established)<\/li><li>Repaglinide (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Riluzole (theoretical)<\/li><li>Rimexolone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Ropivacaine (theoretical)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Tacrine (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Torsemide (theoretical)<\/li><li>Treprostinil (theoretical)<\/li><li>Triamcinolone (theoretical)<\/li><li>Triamterene (theoretical)<\/li><li>Ulipristal (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Warfarin (theoretical)<\/li><li>Zileuton (theoretical)<\/li><li>Zolmitriptan (theoretical)<\/li><\/ul>"}}},"5":{"id":"930367-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Alopecia (10% or greater), Discoloration of skin (10% or greater)<\/li><li><b>Gastrointestinal:<\/b>Nausea (10% or greater), Vomiting (10% or greater)<\/li><li><b>Hematologic:<\/b>Anemia (10% or greater), Leukopenia (10% or greater), Lymphocytopenia (10% or greater), Neutropenia (10% or greater), Thrombocytopenia (10% or greater)<\/li><li><b>Neurologic:<\/b>Asthenia (10% or greater)<\/li><li><b>Renal:<\/b>Urine color abnormal (10% or greater)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Bundle branch block (1% to less than 10%), Cardiac dysrhythmia (0.1% to less than 1%), Congestive heart failure (1% to less than 10%), Decreased cardiac function (1% to less than 10%), Heart failure<\/li><li><b>Gastrointestinal:<\/b>Rectal hemorrhage (0.1% to less than 1%), Salmonella gastroenteritis (0.1% to less than 1%)<\/li><li><b>Hematologic:<\/b>Febrile neutropenia (1% to less than 10%), Hematologic neoplasm (0.1% to less than 1%), Neutropenia, Grade 3 to 4, Pancytopenia (0.1% to less than 1%)<\/li><li><b>Neurologic:<\/b>Meningitis (0.1% to less than 1%), Oral paresthesia (0.1% to less than 1%)<\/li><li><b>Renal:<\/b>Oliguria (0.1% to less than 1%)<\/li><li><b>Respiratory:<\/b>Pleural effusion (0.1% to less than 1%), Pneumonitis (0.1% to less than 1%)<\/li><li><b>Other:<\/b>Cellulitis (0.1% to less than 1%), Shock (0.1% to less than 1%)<\/li><\/ul>"},"6":{"id":"930367-s-6","title":"Drug Name Info","sub":{"2":{"id":"930367-s-6-19","title":"Class","mono":"<ul><li>Anthracycline<\/li><li>Antineoplastic Agent<\/li><\/ul>"},"3":{"id":"930367-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"930367-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>avoid contact with eyes<\/li><li>each pixantrone dimaleate vial contains pixantrone base 29 mg; use pixantrone base to calculate the required dose<\/li><li>reconstitute with 5 mL NS (resulting concentration, 5.8 mg\/mL) and further dilute by injecting the required dose into 250-mL NS infusion bag; final concentration of pixantrone base in infusion bag should be less than 580 mcg\/mL; use immediately; store no longer than 24 hours at room temperature (15 to 25 degrees C) after reconstituted<\/li><li>lyophilized, dark blue powder for solution for infusion; solution remains dark blue after reconstitution and dilution<\/li><li>IV use only; single-use vials; infuse slowly over at least 60 minutes with a polyethersulfone, acrylic, or cellulose acetate 0.2 micrometer pore in-line filter<\/li><\/ul>"}}}